Your browser doesn't support javascript.
loading
Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia.
Farrell, R; Zaunders, J; Poynten, I M; Anderson, L; Evans, L.
Affiliation
  • Farrell R; Chris O'Brien Lifehouse Hospital, Camperdown, Sydney, New South Wales 2050, Australia.
  • Zaunders J; Sydney Medical School, University of Sydney, New South Wales 2006, Australia.
  • Poynten IM; NSW State Reference Labaoratory for HIV, Centre for Applied Medical Research, St Vincents Hospital, New South Wales, Australia.
  • Anderson L; HIV Epidemiology and Prevention Program, The Kirby Institute, University of NSW Kensington, Sydney, New South Wales 2052, Australia.
  • Evans L; HIV Epidemiology and Prevention Program, The Kirby Institute, University of NSW Kensington, Sydney, New South Wales 2052, Australia.
Gynecol Oncol Rep ; 52: 101350, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38445009
ABSTRACT
This is the first report describing detailed T cell responses to viral-like proteins contained in an HPV specific vaccine given in combination with Imiquimod for treatment of persistent VAIN2/3. We postulate that stimulation of the innate immune system with Imiquimod and the specific CD4 and CD8T cell responses following HPV vaccination with Gardasil9@ combined to induce clinical remission in a woman with treatment-refractory disease.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Rep Year: 2024 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Rep Year: 2024 Document type: Article Affiliation country: Australia